ArticleClinical research in cardiology : official journal of the German Cardiac Society2017
Prevalence and prognostic impact of left-sided valve thickening in systemic light-chain amyloidosis.
Article in Clinical research in cardiology : official journal of the German Cardiac Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 37 citations in OpenAlex.
- Role of echocardiography in assessing cardiac amyloidoses: a systematic review.Journal of echocardiography · 2019Pooled it
- Usefulness of Sinus of Valsalva Wall Thickness to PredictCirculation reports · 2026Article
- Recurrent Systemic Embolization in a Patient With Aortic Valve Amyloidosis.Echocardiography (Mount Kisco, N.Y.) · 2025Article
- Echocardiographic risk stratification in light chain and transthyretin amyloidosis: a meta-analysis.European heart journal open · 2025Article
- Myocardial Mechanics and Valvular and Vascular Abnormalities in Cardiac Amyloidosis.Journal of clinical medicine · 2024Review
- Valvular heart disease in patients with cardiac amyloidosis.Heart failure reviews · 2024Review
- Valve disease in cardiac amyloidosis: an echocardiographic score.The international journal of cardiovascular imaging · 2023Article
- Machine Learning Approaches in Diagnosis, Prognosis and Treatment Selection of Cardiac Amyloidosis.International journal of molecular sciences · 2023Review
- CMR-based right ventricular strain analysis in cardiac amyloidosis and its potential as a supportive diagnostic feature.International journal of cardiology. Heart & vasculature · 2023Article
- Bad players in AL amyloidosis in the current era of treatment.Expert review of hematology · 2023Article
- Cardiovascular Magnetic Resonance Imaging-Based Right Atrial Strain Analysis of Cardiac Amyloidosis.Biomedicines · 2022Article
- A Machine Learning Challenge: Detection of Cardiac Amyloidosis Based on Bi-Atrial and Right Ventricular Strain and Cardiac Function.Diagnostics (Basel, Switzerland) · 2022Article
- Light Chain Amyloidosis: Epidemiology, Staging, and Prognostication.Methodist DeBakey cardiovascular journal · 2022Review
- The Importance of Multimodality Imaging in the Diagnosis and Management of Patients with Infiltrative Cardiomyopathies: An Update.Diagnostics (Basel, Switzerland) · 2021Review
- Diagnostic and prognostic value of cardiac imaging in amyloidosis.World journal of cardiology · 2020Review
- Multi-modality imaging of cardiac amyloidosis: Contemporary update.World journal of radiology · 2020Review
- Mitral and tricuspid stenosis caused by light chain cardiac amyloid deposition.ESC heart failure · 2020Article
- When and how do patients with cardiac amyloidosis die?Clinical research in cardiology : official journal of the German Cardiac Society · 2020Article
- ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2-evidence base and standardized methods of imaging.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2019Article
- Late migration of Edwards SAPIEN 3 transcatheter heart valves: mechanisms and transcatheter treatment options for a rare phenomenon.Clinical research in cardiology : official journal of the German Cardiac Society · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLeft heart valve thickening (LVT) was described in patients with light-chain amyloidosis (AL). This phenomenon reflects likely infiltration of the valve by amyloid proteins. However, the prevalence of LVT and its prognostic value have not been investigated in patients with AL. METHODS AND
resultsComprehensive transthoracic echocardiography was performed at baseline in 150 patients [median age 68 (33-87) years; 59% male] with confirmed AL. The presence of abnormal mitral and/or aortic valve thickening (>3 mm) was assessed in all included patients. Overall, 42% had LVT at the time of diagnosis. Compared to patients without LVT, those with LVT were older and had a more advanced NYHA functional class (63% in patients with NYHA III-IV vs. 33% in NYHA I-II, p < 0.001). They also had higher left ventricular (LV) wall thickness and mass, larger left atrium, higher mitral annulus E/E' ratio and systolic pulmonary artery pressures, and lower LV ejection fraction (all p < 0.05). Patients with more advanced Mayo Clinic stage had a higher incidence of LVT: 58% in stage III vs. 45% in stage II and 5% in stage I (p < 0.001). During a median follow-up of 2 years, 79 deaths occurred. The presence of LVT was significantly associated with reduced 5-year survival (32 ± 7 vs. 64 ± 6%). In multivariate analysis, after adjusting for age, gender, NYHA functional class, and LV ejection fraction, LVT remained significantly associated with higher all-cause mortality (hazard ratio 1.90, 95% CI 1.10-3.34, p = 0.02).
conclusionLeft heart valve thickening is common in patients with AL and is associated with worse functional class, LV systolic and diastolic function, and more advanced stage of the disease. In addition, LVT appears to be a powerful marker of all-cause mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.